Description
Trimebutine exhibits antibacterial and gastrointestinal motility modulating activities; it is clinically used to treat irritable bowel syndrome (IBS). Trimebutine displays antibiotic activity against Escherichia and Pseudomonas. This compound enhances gastrointestinal muscle contractions by inhibiting L-type Ca2+ channels and decreasing Ca2+-sensitive (BK) K+ currents and may also act as an agonist at opioid receptors.